Fig. 3: In vitro characterization of vaccine-induced polyclonal sera: inhibition of liver stage development assay (ILSDA) and immunofluorescence assay (IFA). | npj Vaccines

Fig. 3: In vitro characterization of vaccine-induced polyclonal sera: inhibition of liver stage development assay (ILSDA) and immunofluorescence assay (IFA).

From: Comparison of major, minor and junctional circumsporozoite protein epitopes for malaria vaccine design

Fig. 3

A ILSDA using Addavax-adjuvanted sera conducted at 1:10, 1:50, and 1:150 serum dilutions. Mean values with 95% confidence intervals are plotted. While all groups retained significantly higher inhibition compared to naïve sera at a 1:150 dilution, p values for only inter-epitope (i.e. major vs. minor and junctional+minor repeat) differences in inhibition are indicated. B IFA using Addavax-adjuvanted sera against fixed P. falciparum NF54 sporozoites (top) or fixed transgenic PbPf sporozoites (bottom). The numbers below each panel represent end-point titers.

Back to article page